Literature DB >> 21458074

The impact of change in visual field on health-related quality of life the los angeles latino eye study.

Cecilia M Patino1, Rohit Varma, Stanley P Azen, David V Conti, Michael B Nichol, Roberta McKean-Cowdin.   

Abstract

PURPOSE: To assess the impact of change in visual field (VF) on change in health-related quality of life (HRQoL) at the population level.
DESIGN: Prospective cohort study. PARTICIPANTS: Three thousand one hundred seventy-five Los Angles Latino Eye Study participants.
METHODS: Objective measures of VF and visual acuity and self-reported HRQoL were collected at baseline and at the 4-year follow-up. Analysis of covariance was used to evaluate mean differences in change of HRQoL across severity levels of change in VF and to test for effect modification by covariates. MAIN OUTCOME MEASURES: General and vision-specific HRQoL.
RESULTS: Of 3175 participants, 1430 (45%) showed a change in VF (≥1 decibel [dB]) and 1715 (54%) reported a clinically important change (≥5 points) in vision-specific HRQoL. Progressive worsening and improvement in the VF were associated with increasing losses and gains in vision-specific HRQoL for the composite score and 10 of its 11 subscales (all P(trend)<0.05). Losses in VF of more than 5 dB and gains of more than 3 dB were associated with clinically meaningful losses and gains in vision-specific HRQoL, respectively. Areas of vision-specific HRQoL most affected by greater losses in VF were driving, dependency, role-functioning, and mental health. The effect of change in VF (loss or gain) on mean change in vision-specific HRQoL varied by level of baseline vision loss (in VF, visual acuity, or both) and by change in visual acuity (all P(interaction)<0.05). Those with moderate or severe VF loss at baseline and with a more than 5 dB loss in VF during the study period had a mean loss of vision-specific HRQoL of 11.3 points, whereas those with no VF loss at baseline had a mean loss of 0.97 points. Similarly, with a more than 5 dB loss in VF and baseline visual acuity impairment (mild or severe), there was a loss in vision-specific HRQoL of 10.5 points, whereas with no visual acuity impairment at baseline, there was a loss of vision-specific HRQoL of 3.7 points.
CONCLUSIONS: Both losses and gains in VF produce clinically meaningful changes in vision-specific HRQoL. In the presence of pre-existing vision loss (VF and visual acuity), similar levels of VF change produce greater losses in QOL.
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21458074      PMCID: PMC3129408          DOI: 10.1016/j.ophtha.2010.12.018

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  47 in total

1.  Quality of life measures in health care. I: Applications and issues in assessment.

Authors:  R Fitzpatrick; A Fletcher; S Gore; D Jones; D Spiegelhalter; D Cox
Journal:  BMJ       Date:  1992-10-31

2.  A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity.

Authors:  J Ware; M Kosinski; S D Keller
Journal:  Med Care       Date:  1996-03       Impact factor: 2.983

3.  The impact of visual impairment and eye disease on vision-related quality of life in a Mexican-American population: proyecto VER.

Authors:  Aimee Teo Broman; Beatriz Munoz; Jorge Rodriguez; Rosario Sanchez; Harry A Quigley; Ronald Klein; Robert Snyder; Sheila K West
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-11       Impact factor: 4.799

4.  Measurement of health status. Ascertaining the minimal clinically important difference.

Authors:  R Jaeschke; J Singer; G H Guyatt
Journal:  Control Clin Trials       Date:  1989-12

5.  Cumulative illness rating scale.

Authors:  B S Linn; M W Linn; L Gurel
Journal:  J Am Geriatr Soc       Date:  1968-05       Impact factor: 5.562

6.  Glaucoma and survival: the National Health Interview Survey 1986-1994.

Authors:  David J Lee; Orlando Gómez-Marín; Byron L Lam; D Diane Zheng
Journal:  Ophthalmology       Date:  2003-08       Impact factor: 12.079

7.  Minimum important difference between patients with rheumatoid arthritis: the patient's perspective.

Authors:  G A Wells; P Tugwell; G R Kraag; P R Baker; J Groh; D A Redelmeier
Journal:  J Rheumatol       Date:  1993-03       Impact factor: 4.666

8.  The impact of visual impairment on self-reported visual functioning in Latinos: The Los Angeles Latino Eye Study.

Authors:  Denise R Globe; Joanne Wu; Stanley P Azen; Rohit Varma
Journal:  Ophthalmology       Date:  2004-06       Impact factor: 12.079

9.  The Los Angeles Latino Eye Study: design, methods, and baseline data.

Authors:  Rohit Varma; Sylvia H Paz; Stanley P Azen; Ronald Klein; Denise Globe; Mina Torres; Chrisandra Shufelt; Susan Preston-Martin
Journal:  Ophthalmology       Date:  2004-06       Impact factor: 12.079

10.  Quality of life and functional status measures in patients with head and neck cancer.

Authors:  L L D'Antonio; G J Zimmerman; D F Cella; S A Long
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1996-05
View more
  14 in total

1.  Estimating minimally important differences for two vision-specific quality of life measures.

Authors:  Brenda W Gillespie; David C Musch; Leslie M Niziol; Nancy K Janz
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-06-06       Impact factor: 4.799

2.  Providing prescheduled appointments as a strategy for improving follow-up compliance after community-based glaucoma screening: results from an urban underserved population.

Authors:  Tavé van Zyl; Zhuo Su; Elaine Zhou; Ryan K Wong; Amir Mohsenin; Spencer Rogers; James C Tsai; Susan H Forster
Journal:  J Community Health       Date:  2015-02

Review 3.  [Self-reported vision in (gerontological) health services research and practice-an opening plea].

Authors:  J Köberlein-Neu; A Seifert; I Himmelsbach
Journal:  Ophthalmologe       Date:  2018-10       Impact factor: 1.059

Review 4.  Neuro-protection and neuro-regeneration of the optic nerve: recent advances and future directions.

Authors:  Kimberly K Gokoffski; Micalla Peng; Basheer Alas; Phillip Lam
Journal:  Curr Opin Neurol       Date:  2020-02       Impact factor: 5.710

5.  Predicting progression of glaucoma from rates of frequency doubling technology perimetry change.

Authors:  Daniel Meira-Freitas; Andrew J Tatham; Renato Lisboa; Tung-Mei Kuang; Linda M Zangwill; Robert N Weinreb; Christopher A Girkin; Jeffrey M Liebmann; Felipe A Medeiros
Journal:  Ophthalmology       Date:  2013-11-26       Impact factor: 12.079

6.  Associations between self-rated vision score, vision tests, and self-reported visual function in the Salisbury Eye Evaluation Study.

Authors:  Mahmood El-Gasim; Beatriz Munoz; Sheila K West; Adrienne W Scott
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-09-27       Impact factor: 4.799

7.  Factors Associated With Ocular Health Care Utilization Among Hispanics/Latinos: Results From an Ancillary Study to the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).

Authors:  Laura A McClure; D Diane Zheng; Byron L Lam; Stacey L Tannenbaum; Charlotte E Joslin; Sonia Davis; Daniel López-Cevallos; Marston E Youngblood; Zhu-Ming Zhang; Claudia Pulido Chambers; David J Lee
Journal:  JAMA Ophthalmol       Date:  2016-03       Impact factor: 7.389

8.  Impact of Visual Field Loss on Vision-Specific Quality of Life in African Americans: The African American Eye Disease Study.

Authors:  Dominic J Grisafe; Rohit Varma; Bruce S Burkemper; Benjamin Y Xu; Mina Torres; Alicia Fairbrother-Crisp; Cecilia M Patino; Roberta McKean-Cowdin
Journal:  Am J Ophthalmol       Date:  2021-02-08       Impact factor: 5.488

9.  Choroidal metastasis from non-small-cell lung cancer responsive to Osimertinib: a case report : Efficacy of a third-generation epidermal growth factor tyrosine kinase inhibitor.

Authors:  Morara Mariachiara; Ruatta Celeste; Foschi Federico; Balducci Nicole; Ciardella Antonio
Journal:  Int Ophthalmol       Date:  2017-10-25       Impact factor: 2.031

10.  Choroidal metastasis of non-small cell lung cancer that responded to gefitinib.

Authors:  Iwao Shimomura; Yuji Tada; Gen Miura; Toshio Suzuki; Takuma Matsumura; Kenji Tsushima; Jiro Terada; Ryota Kurimoto; Emiko Sakaida; Ikuo Sekine; Yuichi Takiguchi; Shuichi Yamamoto; Koichiro Tatsumi
Journal:  Case Rep Ophthalmol Med       Date:  2013-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.